Nasdaq

Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01

Generation of additional clinical data allows for a more comprehensive assessment of the full potential of EVX-01, while strengthening the already strong clinical data package Will provide insights ...
Nasdaq

Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and ...

MIAMI, FL, June 24, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic ...
Seeking Alpha

Corvus outlines January data readout for soquelitinib extension study as Phase II atopic dermatitis trial set for Q1 2026

Management reaffirmed that the soquelitinib Phase II atopic dermatitis trial will begin in early Q1 2026, enrolling approximately 200 patients across 70 global sites and including those who have ...
The Manila Times

Vima Therapeutics Announces First Dystonia Patient Dosed in Phase 2 Study and Extension of Series A to $100 Million to Advance Potential First-in-Class Oral Therapy for ...

New $40 million raise brings Series A total to $100M, enabling advancement of VIM0423, a first-in-class oral therapeutic, into Phase 2 trials for isolated dystonia and for Parkinson’s diseaseFirst ...